NCT05390827
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 90 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only those patients scheduled to initiate CAR T Cell therapy at Memorial Sloan Kettering Cancer Center are eligible for Project 2
Exclusions: Patients diagnosed metastatic more than 6 months from initial recruitment for trial
https://ClinicalTrials.gov/show/NCT05390827